Direct-to-Consumer Genetic Testing

A Direct-to-Consumer Genetic Testing is a genetic testing that ...

• AKA: At-Home Genetic Testing.
• See: DNA, Chromosome, RNA, Gene Expression, Biochemical Analysis, 23andMe, Genetic Disorders, Biological Parentage, DNA Paternity Testing, Ancestry, Selective Breeding.

---

---

References

2022

• (Wikipedia, 2022) ⇒ https://en.wikipedia.org/wiki/Genetic_testing#Direct-to-consumer_genetic_testing Retrieved:2022-3-16.
  • Direct-to-consumer (DTC) genetic testing (also called at-home genetic testing) is a type of genetic test that is accessible directly to the consumer without having to go through a health care professional. Usually, to obtain a genetic test, health care professionals such as physicians, nurse practitioners, or genetic counselors acquire their patient's permission and then order the desired test, which may or may not be covered by health insurance. DTC genetic tests, however, allow consumers to bypass this process and purchase DNA tests themselves. DTC genetic testing can entail primarily genealogical/ancestry-related information, health and trait-related information, or both.

    There is a variety of DTC tests, ranging from tests for breast cancer alleles to mutations linked to cystic fibrosis. Possible benefits of DTC testing are the accessibility of tests to consumers, promotion of proactive healthcare, and the privacy of genetic information. Possible additional risks of DTC testing are the lack of governmental regulation, the potential misinterpretation of genetic information, issues related to testing minors, privacy of data, and downstream expenses for the public health care system. In the United States, most DTC genetic test kits are not reviewed by the Food and Drug Administration (FDA), with the exception of a few tests offered by the company 23andMe. Research, Center for Drug Evaluation and (2018-11-03). "Direct-to-Consumer Tests" (in en). FDA. https://www.fda.gov/medical-devices/vitro-diagnostics/direct-consumer-tests. </ref> As of 2019, the tests that have received marketing authorization by the FDA include 23andMe's genetic health risk reports for select variants of BRCA1/BRCA2, pharmacogenetic reports that test for selected variants associated with metabolism of certain pharmaceutical compounds, a carrier screening test for Bloom syndrome, and genetic health risk reports for a handful of other medical conditions, such as celiac disease and late-onset Alzheimer's.

---